BiotechTube

NS-089/NCNP-02 + NS-089/NCNP-02

Phase 2Active
1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Duchenne Muscular Dystrophy (DMD)

Conditions

Duchenne Muscular Dystrophy (DMD)

Trial Timeline

Jun 23, 2021 → Apr 30, 2027

NCT ID
NCT05135663

About NS-089/NCNP-02 + NS-089/NCNP-02

NS-089/NCNP-02 + NS-089/NCNP-02 is a phase 2 stage product being developed by Nippon Shinyaku for Duchenne Muscular Dystrophy (DMD). The current trial status is active. This product is registered under clinical trial identifier NCT05135663. Target conditions include Duchenne Muscular Dystrophy (DMD).

What happened to similar drugs?

2 of 20 similar drugs in Duchenne Muscular Dystrophy (DMD) were approved

Approved (2) Terminated (8) Active (11)
❌Tadalafil + PlaceboEli LillyPhase 3
🔄Viltolarsen + PlaceboNippon ShinyakuPhase 3
🔄ViltolarsenNippon ShinyakuPhase 3
❌fordadistrogene movaparvovecPfizerPhase 3
🔄Ataluren + PlaceboPTC TherapeuticsPhase 3
🔄Ataluren + PLACEBOPTC TherapeuticsPhase 3
🔄AtalurenPTC TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05135663Phase 2Active

Competing Products

20 competing products in Duchenne Muscular Dystrophy (DMD)

See all competitors
ProductCompanyStageHype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)BiotrialPhase 1/2
29
ENTR-601-44 + ENTR-601-44 - matching placeboEntrada TherapeuticsPhase 1/2
29
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
29
Tadalafil + PlaceboEli LillyPhase 3
32
DS-5141bDaiichi SankyoPhase 2
39
DS-5141bDaiichi SankyoPhase 1/2
32
Bocidelpar + PlaceboAstellas PharmaPhase 1
21
scAAV9.U7.ACCAAstellas PharmaPhase 1/2
32
NS-065/NCNP-01Nippon ShinyakuPhase 2
35
Viltolarsen + PlaceboNippon ShinyakuPhase 3
40
ViltolarsenNippon ShinyakuPhase 2
35
NS-065/NCNP-01Nippon ShinyakuPhase 1
29
NS-050/NCNP-03 + PlaceboNippon ShinyakuPhase 1/2
39
NS-089/NCNP-02Nippon ShinyakuPhase 2
42
ViltolarsenNippon ShinyakuPhase 3
36
NS-089/NCNP-02Nippon ShinyakuPhase 1/2
32
NS-065/NCNP-01 + PlaceboNippon ShinyakuPhase 2
35
ACE-031 0.5 mg/kg q4wk + ACE-031 1.0 mg/kg q2wkMerckPhase 2
27
ACE-031 (Extension of cohort 1 from core study, A031-03) + ACE-031 (Extension of cohort 2 from core study, A031-03) + ACE-031 (Extension of cohort 3 from core study, A031-03)MerckPhase 2
27
SatralizumabRochePhase 2
42